Step 3: Sanofi com­mits up to $100M to opt-in on Al­ny­lam’s PhI­II RNAi he­mo­phil­ia tri­al

Al­ny­lam is step­ping up to the start­ing line for a Phase III study of its he­mo­phil­ia drug fi­tusir­an with Sanofi on board as a part­ner. The phar­ma com­pa­ny lined up the opt-in rights un­der their ear­li­er deal to buy a mi­nor­i­ty stake in the biotech for $700 mil­lion. And Sanofi is now com­mit­ted to pro­vid­ing $75 mil­lion in de­vel­op­ment and reg­u­la­to­ry mile­stones fol­low­ing a $25 mil­lion up­front due when Phase III starts in ear­ly 2017.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.